Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections

Genes and Immunity

Volumn 17, Issue 5, 2016, Pages 265-275

  Chinnaswamy, S ^a,b  

^a National Institute of Biomedical Genomics   (India)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ALLERGY; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; GENE LOCUS; GENETIC ASSOCIATION; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T LYMPHOTROPHIC VIRUS; IMMUNE RESPONSE; INNATE IMMUNITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RETROVIRIDAE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS INFECTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

HEPATITIS C; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; INTERLEUKINS; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84973376124     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2016.24     Document Type: Review

References (109)

1. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2002; 4: 69-77.
2. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE et al. IL-28, IL-29 and their class II cytokine receptor IL-28 R. Nat Immunol 2002; 4: 63-68.
3. Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 2010; 21: 237-251.
4. Coccia EM, Severa M, Giacomini E, E, Monneron D, Remoli ME, Julkunen I et al. Viral infection and Toll like receptor agonists induce a differential expression of type I andλ interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34: 796-805.
5. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4: e1000017.
6. Mihm S, Frese M, Meier V, Wietzke-Braun P, Scharf J-G, Bartenschlager R et al. Interferon type I gene expression in chronic hepatitis C. Lab Invest 2004; 84: 1148-1159.
7. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 2008; 180: 2474-2485.
8. Mahlakoiv T, Hernandez P, Gronke K, Diefenbach A, Staeheli P. Leukocytederived IFN-α/β and epithelial IFN-λ constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog 2015; 11: e1004782.
9. Nice TJ, Baldridge MT, McCune BT, Norman JM, Lazear HM, Artyomov M et al. Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity. Science 2015; 347: 269-273.
10. Wack A, Terczyńska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nat Immunol 2015; 16: 802-809.
11. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
12. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
13. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
14. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H et al. Avariant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164-171.
15. Chinnaswamy S. Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions. J Interferon Cytokine Res 2014; 34: 479-497.
16. O'Brien TR, Prokunina-Olsson L, Donnelly RP. IFN-λ4: the paradoxical new member of the interferon lambda family. J Interferon Cytokine Res 2014; 34: 829-838.
17. Key FM, Peter B, Dennis MY, Huerta-Sánchez E, Tang W, Prokunina-Olsson L et al. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet 2014; 10: e1004681.
18. Beutler B. Innate immunity: an overview. Mol Immunol 2004; 40: 845-859.
19. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009; 22: 240-273.
20. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev 2009; 227: 75-86.
21. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 2014; 14: 141-153.
22. Sonnenberg GF, Artis D. Innate lymphoid cells in the initiation, regulation and resolution of inflammation. Nat Med 2015; 21: 698-708.
23. Artis D, Spits H. The biology of innate lymphoid cells. Nature 2015; 517: 293-301.
24. Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol 2015; 135: 626-635.
25. Jackson DJ, Makrinioti H, Rana BM, Shamji BW, Trujillo-Torralbo MB, Footitt J et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med 2014; 190: 1373-1382.
26. Hazenberg MD, Spits H. Human innate lymphoid cells. Blood 2014; 124: 700-709.
27. Hepworth MR, Sonnenberg GF. Regulation of the adaptive immune system by innate lymphoid cells. Curr Opin Immunol 2014; 27: 75-82.
28. Lazear HM, Nice TJ, Diamond MS. Interferon-λ: Immune functions at barrier surfaces and beyond. Immunity 2015; 43: 15-28.
29. Wojno EDT, Artis D. Innate lymphoid cells: balancing immunity, inflammation and tissue repair in the intestine. Cell Host Microbe 2012; 12: 445-457.
30. Hamming OJ, Terczyńska-Dyla E, Vieyres G, Dijkman R, Jørgensen SE, Akhtar H. Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J 2013; 32: 3055-3065.
31. Crotta S, Davidson S, Mahlakoiv T, Desmet CJ, Buckwalter MR, Albert ML et al. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog 2013; 9: e1003773.
32. Siren J, Pirhonen J, Jullkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28 and IL-29. J Immunol 2005; 174: 1932-1937.
33. Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol 2012; 189: 2735-2745.
34. Hillyer P, Mane VP, Schramm LM, Puig M, Verthelyi D, Chen A et al. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligandand cell-dependent. Immunol Cell Biol 2012; 90: 774-783.
35. Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009; 10: 702-714.
36. Lauber C, Vieyres G, Terczyńska-Dyla E, Anggakusuma, Dijkman R, Gad HH et al. Transcriptome analysis reveals a classical interferon signature induced by IFNλ4 in human primary cells. Genes Immun 2015; 16: 414-421.
37. Egli A, Santer DM, ÓShea D, Tyrell DL, Houghton M. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Microbes Infect 2014; 3: e51.
38. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M et al. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun 2007; 8: 254-261.
39. Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C et al. IL-28 A (IFN-λ2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med 2011; 3: 348-361.
40. Hernandez PP, Mahlakoiv T, Yang I, Schwierzeck V, Nguyen N, Guendel F et al. Interferon-l and interleukin 22act synergistically for the induction of interferonstimulated genes and control of rotavirus infection. Nat Immunol 2015; 16: 698-707.
41. Lu YF, Goldstein DB, Urban TJ, Bradrick SS. Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden. Virology 2015; 476: 334-340.
42. Travar M, Vucic M, Petkovic M. Interferon lambda-2 levels in sputum of patients with pulmonary Mycobacterium tuberculosis infection. Scand J Immunol 2014; 80: 43-49.
43. Cannella F, Scagnolari C, Selvaggi C, Stentella P, Recine N, Antonelli G et al. Interferon lambda 1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women. Med Microbiol Immunol 2014; 203: 177-184.
44. Killip MJ, Fodor E, Randall RE. Influenza virus activation of the interferon system. Virus Res 2015; 209: 11-22.
45. Baños-Lara Mdel R, Harvey L, Mendoza A, Simms D, Chouljenko VN, Wakamatsu N et al. Impact and regulation of lambda interferon response in human metapneumovirus infection. J Virol 2015; 89: 730-742.
46. Hermant P, Michiels T. Interferon-λ in the context of viral infections: production, response and therapeutic implications. J Innate Immun 2014; 6: 563-574.
47. Egli A, Levin A, Santer DM, Joyce M, ÓShea D, Thomas BS et al. Immunomodulatory function of interleukin 28B during primary infection with cytomegalovirus. J Infect Dis 2014; 210: 717-727.
48. Fernández-Ruiz M, Corrales I, Arias M, Campistol JM, Giménez E, Crespo J et al. Association between individual and combined SNPs in genes related to innate immunity and incidence of CMV infection in seropositive kidney transplant patients. Am J Transplant 2015; 15: 1323-1335.
49. Bravo D, Solano C, Giménez E, Remigia MJ, Corrales I, Amat P et al. Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. J Med Virol 2014; 86: 838-844.
50. Bibert S, Wojtowicz A, Taffé P, Manuel O, Bernasconi E, Furrer H et al. The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS 2014; 28: 1885-1889.
51. Manuel O, Wójtowicz A, Bibert S, Mueller NJ, van Delden C, Hirsch HH et al. Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. J Infect Dis 2015; 211: 906-914.
52. Treviño A, Lopez M, Vispo E, Aquilera A, Ramos JM, Benito R. Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms. Clin Infect Dis 2012; 55: e1-e4.
53. Assone T, de Souza FV, Gaester KO, Fonseca LA, Luiz Odo C, Malta F et al. IL28B gene polymorphism SNP rs8099917 genotype GG is associated with HTLV-1 carriers. PLoS Negl Trop Dis 2014; 8: e3199.
54. Sanabani SS, Nukui Y, Pereira J, de Costa AC, de Oliveira AC, Pessôa R et al. Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load. BMC Infect Dis 2012; 12: 374.
55. Vallinoto AC, Santana BB, Sá KS, Ferreira TC, Sousa RC, Azevedo VN et al. HTLV-1-associated myelopathy/tropical spastic paraparesis is not associated with SNP rs12979860 of the IL-28B gene. Mediators Inflamm 2015; 2015: 804167.
56. de Sá KS, Santana BB, de Souza Ferreira TC, Sousa RC, Caldas CA, Azevedo VN et al. IL28B gene polymorphisms and Th1/Th2 cytokine levels might be associated with HTLV-associated arthropathy. Cytokine 2016; 77: 79-87.
57. Kamihira S, Usui T, Ichikawa T, Ono N, Morinaga Y, Mori S et al. Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus type-1 mono-infection and co-infection with hepatitis C virus. Virol J 2012; 9: 40.
58. Jeannin S, Costa JM, Poveda JD, Belrose G, Lezin A, Cabie A et al. Absence of association of IFNL3/IL28B rs 12979860 and IFNL4 ss 469415590 polymorphisms with the neurological status of HTLV-1 Afro-Caribbean subjects in Martinique. Retrovirology 2015; 2(Suppl 1): P 61.
59. Leong CR, Oshiumi H, Suzuki T, Matsumoto M, Seya T. Nucleic acid sensors involved in the recognition of HBV in the liver-specific in vivo transfection mouse models-Pattern recognition receptors and sensors for HBV. Med Sci 2015; 3: 16-24.
60. Horner Jr SM, Gale M. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 2013; 19: 879-888.
61. Galmozzi E, Viganó M, Lampertico P. Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? Aliment. Pharmacol Ther 2014; 39: 569-578.
62. Jilg N, Chung RT. One more piece in the interleukin 28B gene puzzle? The case of hepatitis B. Hepatology 2013; 57: 870-872.
63. Takahashi T. Interleukin 28B genetic polymorphism and hepatitis B virus infection. World J Gastroenterol 2014; 20: 12026-12030.
64. Visco-Comandini U, Lapa D, Taibi C, Angeletti C, Capobianchi MR, Garbuglia AR. No impact of interleukin-28B polymorphisms on spontaneous or drug induced hepatitis delta virus clearance. Dig Liver Dis 2014; 46: 348-352.
65. Yilmaz E, Baran B, Soyer OM, Onel M, Onel D, Ormeci AC et al. Effects of polymorphisms in interferon λ3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection. Clin Gastroenterol Hepatol 2014; 12: 1753-1758.
66. Sajadi MM, Shakeri N, Talwani R, Redfield RR. Hepatitis C infection in HIV-1 viral suppressors. AIDS 2010; 24: 1689-1695.
67. Ruiz-Mateos E, Machmach K, Romero-Sanchez MC, Ferrando-Martinez S, Viciana P, Del Val M et al. Hepatitis C virus replication in Caucasian HIV controllers. J Viral Hepat 2011; 18: e350-e357.
68. Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010; 202: 1749-1753.
69. Rallon NI, Restrepo C, Naggie S, Lopez M, Del Romero J, Goldstein D et al. Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. AIDS 2011; 25: 269-271.
70. Salgado M, Kirk GD, Cox A, Rutebemberwa A, Huggins Y, Astemborski J et al. Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors. AIDS 2011; 25: 385-387.
71. Sajadi MM, Shakeri N, Talwani R, Howell CD, Pakyz R, Redfield RR et al. IL28B genotype does not correlate with HIV control in African Americans. Clin Transl Sci 2011; 4: 282-284.
72. Machmach K, Abad-Molina C, Romero-Sánchez MC, Abad MA, Ferrando-Martínez S, Genebat M et al. IL28B single-nucleotide polymorphism rs12979860 is associated with spontaneous HIV control in white subjects. J Infect Dis 2013; 207: 651-655.
73. Machmach K, Abad-Molina C, Romero-Sánchez MC, Dominquez-Molina B, Moyano M, Rodriquez MM et al. IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status inHIV-infected individuals. Clin Microbiol Infect 2015; 21: e1-e4.
74. Real LM, Herrero R, Rivero-Juárez A, Camacho A, Macías J, Vic S et al. IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection. AIDS 2015; 29: 1895-1897.
75. Griffiths SJ, Koegl M, Boutell C, Zenner HL, Crump CM, Pica F et al. A systematic analysis of host factors reveals a Med23-interferon-λ regulatory axis against herpes simplex virus type 1 replication. PLoS Pathog 2013; 9: e1003514.
76. Lang Kuhs KA, Kuniholm MH, Pfeiffer RM, Chen S, Desai S, Edlin BR et al. Interferon lambda 4 genotype is not associated with recurrence of oral or genital herpes. PLoS One 2015; 10: e0138827.
77. Petta S, Grimaudo S, Cammá C, Cabibi D, Di Marco V, Licata G et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with nonalcoholic fatty liver disease. J Hepatol 2012; 56: 1356-1362.
78. Thompson AJ, Clark PJ, Zhu M, Zhu Q, Ge D, Sulkowski MS et al. Genome wideassociation study identifies IL28B polymorphism to be associated with baseline Alt and hepatic necro-inflammatory activity in chronic hepatitis C patients enrolled in the ideal study. Hepatology 2010; 52: 1220 A-1221 A.
79. Garrett ME, Abdelmalek MF, Ashley-Koch A, Hauser MA, Moylan CA, Pang H et al. IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian north American patients. J Hepatol 2013; 58: 402-403.
80. Petta S, Craxi A. Reply to: "IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian north American patients". J Hepatol 2013; 58: 403-404.
81. Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ et al. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun 2015; 6: 6422.
82. Gaudieri S, Lucas M, Lucas A, McKinnon E, Albloushi H, Rauch A et al. Genetic variations in IL28B and allergic disease in children. PLoS One 2012; 7: e30607.
83. Dhariwal J, Edwards MR, Johnston SL. Anti-viral agents: potential utility in exacerbations of asthma. Curr Opin Pharmacol 2013; 13: 331-336.
84. Scagnolari C, Midulla F, Riva E, Monteleone K, Solimini A, Bonci E et al. Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering from bronchiolitis. Virus Res 2012; 165: 236-240.
85. Malhotra S, Morcillo-Suárez C, Brassat D, Goertsches R, Lechner-Scott J, Urcelay E et al. IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis. J Neuroimmunol 2011; 239: 101-104.
86. Egli A, Santer DM, ÓShea D, Barakat K, Syedbasha M, Vollmer M et al. IL-28B is a regulator of B- and T- cell vaccine responses against influenza. PLoS Pathog 2014; 10: e1004556.
87. Iversen MB, Paludan SR. Mechanisms of type III interferon expression. J Interferon Cytokine Res 2010; 30: 573-578.
88. Durbin RK, Kotenko SV, Durbin JE. Interferon induction and function at the mucosal surface. Immunol Rev 2013; 255: 25-39.
89. Chinnaswamy S, Bhushan A, Behera AK, Ghosh S, Rampurkar V, Chandra V et al. Roles for transcription factors Sp1, NF-κB, IRF3, and IRF7 in expression of the human IFNL4 gene. Viral Immunol 2016; 29: 49-63.
90. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210: 1109-1116.
91. Smith KR, Suppiah V, O'Connor K, Berg T, Weltman M, Abate ML et al. Identification of improved IL28B SNPs and haplotypes for prediction of drug response inn treatment of hepatitis C using massively parallel sequencing in a crosssectional European cohort. Genome Med 2011; 3: 57.
92. Amanzada A, Kopp W, Spengler U, Ramadori G, Mihm S. Interferon-λ4 (IFNL4) transcript expression in human liver tissue samples. PLoS One 2013; 8: e84026.
93. Murakawa M, Asahina Y, Nakagawa M, Sakamoto N, Nitta S, Kusano-Kitazume A et al. Impaired induction of interleukin 28B and expression of interferon λ4 associated with nonresponse to interferon-based therapy in chronic hepatitis C. J Gastroenterol Hepatol 2015; 30: 1075-1084.
94. Noureddin M, Rotman Y, Zhang F, Park H, Rehermann B, Thomas E et al. Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: a phenotype-genotype correlation study. Genes Immun 2015; 16: 321-329.
95. Konishi H, Motomura T, Matsumoto Y, Harimoto N, Ikegami T, Yoshizumi T et al. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant. J Viral Hepat 2014; 21: 397-404.
96. Honda M, Shirasaki T, Shimakami T, Sakai A, Horii R, Arai K et al. Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. Hepatology 2014; 59: 828-838.
97. Chinnaswamy S, Chatterjee S, Boopathi R, Mukherjee S, Bhattacharjee S, Kundu SK. A single nucleotide polymorphism associated with hepatitis C virus infections located in the distal region of the IL28B promoter influences NF-κB mediated gene transcription. PLoS One 2013; 8: e75495.
98. McFarland AP, Horner SM, Jarret A, Joslyn RC, Bindewald E, Shapiro BA et al. The favourable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced micro RNAs. Nat Immunol 2014; 15: 72-79.
99. du lulio J, Ciuffi A, Fitzmaurice K, Kelleher D, Rotger M, Fellay J et al. Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology 2011; 53: 1446-1454.
100. Lu YF, Mauger DM, Goldstein DB, Urban TJ, Weeks KM, Bradrick SS. IFNL3 mRNA structure is remodelled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci Rep 2015; 5: 16037.
101. Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M. Genetic variation of the IL-28B promoter affecting gene expression. PLoS One 2011; 6: e26620.
102. Thong VD, Wasitthankasem R, Tangkijvanich P, Vongpunsawad S, Poovorawan Y. Prevalence of thymine-adenine dinucleotide repeat, IL28B and IFNL4 in Thai population and correlation with spontaneous clearance and treatment outcome of hepatitis C infection. PLoS One 2015; 10: e0125400.
103. Masaki N, Sugiyama M, Shimada N, Tanaka Y, Nakamuta M, Izumi N et al. Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C. J Gastroenterol Hepatol 2014; 29: 1996-2005.
104. Hiramine S, Sugiyama M, Furusyo N, Uto H, Ido A, Tsubouchi H et al. A thymineadenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus. J Gastroenterol 2015; 50: 1069-1077.
105. Kurbanov F, Kim Y, Latanich R, Chaudhari P, El-Diwany R, Knabel M et al. IFNL3 genotype is associated with differential induction of IFNL3 in primary human hepatocytes. Antivir Ther 2015; 20: 805-814.
106. Terczyńska-Dyla E, Bibert S, Duong FH, Krol I, Jørgensen S, Collinet E et al. Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun 2014; 5: 5699.
107. ÓBrien TR, Pfeiffer RM, Paquin A, Lang kuhs KA, Chen S, Bonkovsky HL et al. comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol 2015; 63: 1103-1110.
108. Shi X, Pan Y, Wang M, Wang D, Li W, Jiang T et al. IL-28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One 2012; 7: e37054.
109. Rallón NI, Soriano V, Naggie S, Restrepo C, Hutchison J, Vispo E et al. Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. J Antimicrob Chemother 2012; 67: 1246-1249.